{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T02:42:27Z","timestamp":1783219347611,"version":"3.54.6"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.ejpb.2014.05.018","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T09:30:43Z","timestamp":1401701443000},"page":"406-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route"],"prefix":"10.1016","volume":"88","author":[{"given":"Nhung T.T.","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haran","family":"Sivakumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Harrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul N.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Davis-Poynter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G.A.","family":"Coombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2014.05.018_b0005","unstructured":"WHO, Towards Universal Access: Scaling up Priority HIV\/AIDS Interventions in the Health Sector, 2010."},{"key":"10.1016\/j.ejpb.2014.05.018_b0010","unstructured":"UNAIDS, Global Report: UNAIDS Report on the Global AIDS Epidemic 2012, 2012."},{"key":"10.1016\/j.ejpb.2014.05.018_b0015","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.ejpb.2014.05.018_b0020","unstructured":"Microbicide Trial Network, MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, A Major HIV Prevention Study in Women, 2011."},{"key":"10.1016\/j.ejpb.2014.05.018_b0025","unstructured":"J.M. Marrazzo, G. Ramjee, G. Nair, T. Palanee, B. Mkhize, C. Nakabbiito, M. Taljaard, J. Piper, K. Gomez Feliciano, M. Chirenje, Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir\/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN-003), in: Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 2013."},{"key":"10.1016\/j.ejpb.2014.05.018_b0030","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1128\/AAC.01431-12","article-title":"A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis","volume":"56","author":"Johnson","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2014.05.018_b0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejpb.2010.10.010","article-title":"Sustained release of proteins from a modified vaginal ring device","volume":"77","author":"Morrow","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2014.05.018_b0040","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1002\/jps.21331","article-title":"Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1","volume":"97","author":"Gupta","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.05.018_b0045","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/QAD.0b013e32832af57c","article-title":"Sustained release of microbicides by newly engineered vaginal rings","volume":"23","author":"Saxena","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ejpb.2014.05.018_b0050","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s10461-012-0215-0","article-title":"High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women","volume":"16","author":"van der Straten","year":"2012","journal-title":"AIDS Behav."},{"key":"10.1016\/j.ejpb.2014.05.018_b0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijpharm.2006.06.026","article-title":"Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide","volume":"325","author":"Woolfson","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.05.018_b0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/aid.2008.0184","article-title":"Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring","volume":"25","author":"Romano","year":"2009","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.ejpb.2014.05.018_b0065","unstructured":"Microbicide Trials Network, Phase III Safety and Effectiveness Study of the Dapivirine Ring, 2013."},{"key":"10.1016\/j.ejpb.2014.05.018_b0070","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s13346-012-0101-3","article-title":"Development of a UC781 releasing polyethylene vinyl acetate vaginal ring","volume":"2","author":"McConville","year":"2012","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2014.05.018_b0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0168-3659(03)00260-8","article-title":"In vitro release of nonoxynol-9 from silicone matrix intravaginal rings","volume":"91","author":"Malcolm","year":"2003","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2014.05.018_b0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0378-5173(01)00900-0","article-title":"In vitro release properties of etonogestrel and ethinyl estradiol from a contraceptive vaginal ring","volume":"232","author":"van Laarhoven","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2014.05.018_b0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0885328212437393","article-title":"Development of intra-vaginal matrices from polycaprolactone for sustained release of antimicrobial agents","volume":"28","author":"Dang","year":"2013","journal-title":"J. Biomater. Appl."},{"key":"10.1016\/j.ejpb.2014.05.018_b0090","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1002\/jps.23684","article-title":"An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV","volume":"102","author":"Dang","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.05.018_b0095","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.00976-10","article-title":"Combinatorial approaches to the prevention and treatment of HIV-1 infection","volume":"55","author":"Pirrone","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2014.05.018_b0100","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1097\/QAD.0b013e3283491f89","article-title":"Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination","volume":"25","author":"Schader","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.ejpb.2014.05.018_b0105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.antiviral.2006.05.013","article-title":"Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies?","volume":"71","author":"Martinez","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejpb.2014.05.018_b0110","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejps.2009.11.007","article-title":"Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir","volume":"39","author":"Johnson","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.05.018_b0115","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ejps.2012.12.002","article-title":"A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action","volume":"48","author":"Fetherston","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.05.018_b0120","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/AAC.05662-11","article-title":"Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring","volume":"56","author":"Moss","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2014.05.018_b0125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","article-title":"A vaginal fluid simulant","volume":"59","author":"Owen","year":"1999","journal-title":"Contraception"},{"key":"10.1016\/j.ejpb.2014.05.018_b0130","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"key":"10.1016\/j.ejpb.2014.05.018_b0135","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0165-6147(83)90490-X","article-title":"Analysis of combined drug effects: a new look at a very old problem","volume":"4","author":"Chou","year":"1983","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejpb.2014.05.018_b0140","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/jps.2600521210","article-title":"Mechanism of sustained-action medication. theoretical analysis of rate of release of solid drugs dispersed in solid matrices","volume":"52","author":"Higuchi","year":"1963","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.05.018_b0145","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/jbm.820170615","article-title":"A model of dissolution-controlled solute release from porous drug delivery polymeric systems","volume":"17","author":"Peppas","year":"1983","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.ejpb.2014.05.018_b0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0168-3659(99)00083-8","article-title":"Mechanism of drug release from poly(l-lactic acid) matrix containing acidic or neutral drugs","volume":"60","author":"Miyajima","year":"1999","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2014.05.018_b0155","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1128\/AAC.06284-11","article-title":"Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model","volume":"56","author":"Cost","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2014.05.018_b0160","doi-asserted-by":"crossref","DOI":"10.1002\/jps.23684","article-title":"An evaluation of polycaprolactone matrices for vaginal delivery of the antiviral, tenofovir, in preventing heterosexual transmission of HIV","author":"Dang","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2014.05.018_b0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0031-6997(25)07221-7","article-title":"Antagonisms and antagonists","volume":"9","author":"Loewe","year":"1957","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2014.05.018_b0170","series-title":"Enzyme and Metabolic Inhibitors","author":"Webb","year":"1963"},{"key":"10.1016\/j.ejpb.2014.05.018_b0175","unstructured":"T.-C. Chou, N. Martin, CompuSyn for Drug Combinations and for General Dose-Effect Analysis User\u2019s Guide, 2005."},{"key":"10.1016\/j.ejpb.2014.05.018_b0180","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.2649","article-title":"A quantitative basis for antiretroviral therapy for HIV-1 infection","volume":"18","author":"Jilek","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejpb.2014.05.018_b0185","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2014.05.018_b0190","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1742-4690-6-44","article-title":"The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study","volume":"6","author":"Feng","year":"2009","journal-title":"Retrovirology"},{"key":"10.1016\/j.ejpb.2014.05.018_b0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcv.2004.02.009","article-title":"Antiviral drugs in current clinical use","volume":"30","author":"De Clercq","year":"2004","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.ejpb.2014.05.018_b0200","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0149-2918(98)80031-3","article-title":"Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions","volume":"20","author":"Warren Beach","year":"1998","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejpb.2014.05.018_b0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1600-0897.2010.00932.x","article-title":"Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections","volume":"65","author":"Herold","year":"2011","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.ejpb.2014.05.018_b0215","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/AAC.00547-13","article-title":"Pharmacokinetics of a multipurpose pod-intravaginal ring simultaneously delivering five drugs in an ovine model","volume":"57","author":"Moss","year":"2013","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641114001714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641114001714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T05:51:46Z","timestamp":1746251506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641114001714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0939641114001714"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.05.018","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2014.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}